Most Popular Articles : Journal of Immunotherapy

Secondary Logo

Journal Logo

Most Popular Articles

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Qin, Jim S.; Johnstone, Timothy G.; Baturevych, Alex; More

Journal of Immunotherapy. 43(4):107-120, May 2020.

A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors

Guo, Mengni; Liu, Jieying; Miao, Ruoyu; More

Journal of Immunotherapy. 45(9):389-395, November/December 2022.

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication

Buti, Sebastiano; Basso, Umberto; Giannarelli, Diana; More

Journal of Immunotherapy. : November 04, 2022

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

Wang, Xueyin; Sandberg, Mark L.; Martin, Aaron D.; More

Journal of Immunotherapy. 44(8):292-306, October 2021.

Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma

Bishop, Andrew J.; Amini, Behrang; Lin, Heather; More

Journal of Immunotherapy. 45(8):374-378, October 2022.

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis

Lin, Chang-Ting; Su, Po-Jung; Huang, Shih-Yu; More

Journal of Immunotherapy. 45(9):407-414, November/December 2022.

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

Lambert, Stacie L.; Zhang, Chun; Guo, Claire; More

Journal of Immunotherapy. 45(3):167-179, April 2022.

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

Fotin-Mleczek, Mariola; Duchardt, Katharina M.; Lorenz, Christina; More

Journal of Immunotherapy. 34(1):1-15, January 2011.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

Diem, Stefan; Fässler, Mirjam; Bomze, David; More

Journal of Immunotherapy. 42(3):89-93, April 2019.

The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens

Guest, Ryan D; Hawkins, Robert E; Kirillova, Natalia; More

Journal of Immunotherapy. 28(3):203-211, May-June 2005.

A Clinical Development Paradigm for Cancer Vaccines and Related Biologics

Hoos, Axel; Parmiani, Giorgio; Hege, Kristen; More

Journal of Immunotherapy. 30(1):1-15, January 2007.

Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study

Hendriks, Natasja; Koeneman, Margot M.; van de Sande, Anna J.M.; More

Journal of Immunotherapy. 45(3):180-186, April 2022.

Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells

Shrestha, Bishwas; Zhang, Yongliang; Yu, Bin; More

Journal of Immunotherapy. 43(3):79-88, April 2020.

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

Nishida, Sumiyuki; Morimoto, Soyoko; Oji, Yusuke; More

Journal of Immunotherapy. 45(1):56-66, January 2022.

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

Fischer, Jeannette; Paret, Claudia; El Malki, Khalifa; More

Journal of Immunotherapy. 40(5):187-195, June 2017.

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Hollyman, Daniel; Stefanski, Jolanta; Przybylowski, Mark; More

Journal of Immunotherapy. 32(2):169-180, February-March 2009.

Chimeric Antigen Receptor–modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model

Teng, Ruidi; Zhao, Jingjing; Zhao, Yiding; More

Journal of Immunotherapy. 42(2):33-42, February/March 2019.

Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events

Oswalt, Cameron J.; Al-Rohil, Rami N.; Theivanthiran, Bala; More

Journal of Immunotherapy. 45(6):284-290, July/August 2022.

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, Richard A.; Chinnasamy, Nachimuthu; Abate-Daga, Daniel; More

Journal of Immunotherapy. 36(2):133-151, February-March 2013.

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

Lindenberg, Melanie A.; Retèl, Valesca P.; van den Berg, Joost H.; More

Journal of Immunotherapy. 41(9):413-425, November/December 2018.

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

Dulos, John; Carven, Gregory J.; van Boxtel, Susan J.; More

Journal of Immunotherapy. 35(2):169-178, February-March 2012.

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Nishida, Sumiyuki; Koido, Shigeo; Takeda, Yutaka; More

Journal of Immunotherapy. 37(2):105-114, February/March 2014.

DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection

Chandra, Janin; Dutton, Julie L.; Li, Bo; More

Journal of Immunotherapy. 40(2):62-70, February/March 2017.

Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors

Zhao, Lijun; Li, Yang; Jiang, Ning; More

Journal of Immunotherapy. 45(4):210-216, May 2022.

Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release

Amann, Maria; dÁrgouges, Sandrine; Lorenczewski, Grit; More

Journal of Immunotherapy. 32(5):452-464, June 2009.

The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer Cell Cytotoxicity Against Melanoma Cell Lines In Vitro

Dupuis, Maria L.; Fiori, Valentina; Soriani, Alessandra; More

Journal of Immunotherapy. 38(9):357-370, November/December 2015.

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma

Monk, Paul; Lam, Elaine; Mortazavi, Amir; More

Journal of Immunotherapy. 37(3):180-186, April 2014.

Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Petrelli, Fausto; Grizzi, Giulia; Ghidini, Michele; More

Journal of Immunotherapy. 43(1):1-7, January 2020.

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients

Boudewijns, Steve; Westdorp, Harm; Koornstra, Rutger H.T.; More

Journal of Immunotherapy. 39(6):241-248, July/August 2016.

Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation

Kállay, Krisztián; Kassa, Csaba; Réti, Marienn; More

Journal of Immunotherapy. 41(3):158-163, April 2018.

Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

Wang, Xiuli; Naranjo, Araceli; Brown, Christine E.; More

Journal of Immunotherapy. 35(9):689-701, November-December 2012.

A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer

Kotecki, Nuria; Vuagnat, Perrine; O’Neil, Bert H.; More

Journal of Immunotherapy. 44(7):264-275, September 2021.

CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1-Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma

de Vos, Luka; Carrillo Cano, Tzaitel Maria; Zarbl, Romina; More

Journal of Immunotherapy. 45(7):324-334, September 2022.

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial

Cohn, Allen; Morse, Michael A.; O’Neil, Bert; More

Journal of Immunotherapy. 41(3):141-150, April 2018.

A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer

Suzuki, Nobuaki; Hazama, Shoichi; Ueno, Tomio; More

Journal of Immunotherapy. 37(1):36-42, January 2014.